We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 2.99% | 27.60 | 27.60 | 28.00 | 28.00 | 27.00 | 27.40 | 613,915 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 66.64M | -10.1M | -0.0222 | -12.61 | 127.38M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/11/2020 16:06 | OOpS! Sorry, didn't see your post hastings. CD | cambridgedon | |
11/11/2020 16:04 | Write up after speaking with Julian Baines this morning. Hopefully of use and look forward to further thoughts from Wan etal. | hastings | |
11/11/2020 09:17 | Thank you for explaining wan. | mirandaj | |
11/11/2020 09:02 | Mirandaj...Thanks. Fwiw, the extraction buffer/sample collection (hopefully ATM) is fundamental to the performance of the antigen tests. In other words, the extraction buffer stabilises and extracts the RNA, so I can't see how a mask that samples untreated breath/untreated saliva would be able to offer the same level of specificity or sensitivity as a lateral flow test. If PrimeStore ATM is used as the sample collection element (swab inserted into it), it also decontaminates the sample and yet it preserves protein-protein interactions and apparently 'enhances' (enables?) antigen testing. | wan | |
11/11/2020 08:30 | Wan, I was wondering what had happened to this as have not seen any more on it. For interest anyway. | mirandaj | |
11/11/2020 08:21 | Given EKF varying products I will be amazed if they do not pick up significant orders from these given their success to date with Leicester University from the £40b the big question is how much currently the market isn't giving much if any credit for this. AIMHO GLA BTG | btgman | |
11/11/2020 07:47 | The big question then, is the new PrimeStore AMT being used in the pilot? Time will tell (I note that Thermo Fisher appears to be selling PrimeStore ATM). I can see that the Government has put out the largest tender to date for lateral flow tests (and not the recent ones won by Abbott and Innova, which are eclipsed by the new tender in terms of value!). For obvious reasons I have also been monitoring the Governments efforts in seeking to procure sample collection consumables for COVID-19 'antigen' testing in order to scale up testing to meet forecast demand for winter. And I can report they have been active in this regard and again this fits in with the roll out of mass antigen testing. | wan | |
11/11/2020 07:42 | Worth noting too, that EKF is working with a number of Universities across the UK. | hastings | |
11/11/2020 07:37 | Students 'will' be tested on the way out.........and tested on the way in in January! | wan | |
11/11/2020 07:35 | Recall that I posted the following recently - 4 days ago University of Leicester : ‘At the University of Leicester we have established an asymptomatic SARS-CoV-2 screening programme, providing reassurance and support to our staff and students on campus with the aim to reduce viral transmission. By choosing PrimeStore Molecular Transport media with its viral inactivation properties, we are ensuring the safe transportation and processing of participants samples and ensuring protection for our staff. Furthermore, we have the reassurance of RNA stabilisation, protecting sample integrity at room temperature without the need for additional storage requirements. EFK have provided excellent customer service throughout. Offering a fast and friendly personalised approach, addressing all of our technical considerations and fully supporting our needs.’ Live just a few minutes ago on the BBC was a new pilot 'antigen' testing program in Leicester University. So, will this replace the previous scheme that EKF were supporting using PrimeStore MTM or is it complimentary? I think it's complimentary, in that it is recommended that in certain scenarios a confirmatory PCR test will be required - FDA guidance - "it may be necessary to confirm a rapid antigen test result with a nucleic acid test, especially if the result of the antigen test is inconsistent with the clinical context". Running the two operations fits with the pilot nature, and fits in with the Governments intended roll out of mass testing across 'all' universities, which I believe will begin proper early December to enable a safe return home for Christmas. | wan | |
10/11/2020 19:41 | You don't know know why it dropped ... but you still want to go for it. Go kill it champ - the world is yours. | tongosti | |
10/11/2020 18:05 | You're ready now Andrew! | hastings | |
10/11/2020 17:09 | Why it dropped, I really don't know: a good stock, with lots going for it. I may actually buy more, hmmm! | andrewbaker | |
10/11/2020 14:22 | Nice bounce. Sanity being restored :o)) | rivaldo | |
10/11/2020 12:48 | Time to hear the cash register ring again. Covered my final third for another +5% and change. +48% trading both sides over the last few weeks. Gracias Senor Mercado | tongosti | |
10/11/2020 10:39 | I note that Chris Mills, across his various vehicles, has increased the holding in Source Bio to over 29% (inline with his holding in EKF) - 10 November 2020|RNS | wan | |
10/11/2020 10:32 | Ok pal - live and let's live as that's what makes a market. I just see volumes skyrocketing today as well on the way down. I am personally happy to ride my short to whatever it takes me so that aside I genuinely wish you luck. | tongosti | |
10/11/2020 10:17 | I now take it back about other diagnostic stocks recovering! But I stick with my view that EKF is differentiated in its diagnostics offering, coronavirus or otherwise, including post any successful development/authoris | wan | |
10/11/2020 09:47 | I see your point of view but do not necessarily agree with your assessment post Pfizer vaccine. It's a long story but suffice to say that market's action confirms how I think about related implications (I made this point immediately after the vaccine news broke out yesterday). In broader terms, to me the ultimate fundamental is the market action and I never play macho with it. Doesn't matter how you cut it, we never make money on our opinions but by being in sync with the market action. Always and without fail (opinions pay off if and only if they positively correlate with market action). | tongosti | |
10/11/2020 09:39 | I agree that markets overreact in either direction. However, it's not as if EKF are over reliant on testing alone, or even the development of a test like some companies are. EKF has significant cash in the bank and generates real positive cash flow. The vaccine news does not change the fact that EKF's full year performance has further exceeded market consensus and will result in record revenues for the year. And the dramatic expansion of testing suggests there could be more in the tank yet. Also, vaccines will add requirements for antibody testing, especially those that complete phase 3 like Pfizer and BioNTech (nb: BioNTech is German). The Kantaro/EKF 'quantitative antibody test is backed up by diverse data and real clinical usage, and I can confirm that that is a major differentiating feature compared to some single use 'qualitative' tests on the market/in development, some of which apparently don't even work! | wan | |
10/11/2020 09:08 | What you are missing is understanding Mr Market. Honestly, this is not tongue in cheek but a genuine comment. There is a two way feedback loop between market action and fundamentals not a one way street like most believe. George Soros calls it Reflexivity. I would go read I'm about it if I were you. Cheers. | tongosti | |
10/11/2020 08:57 | What am I missing, other diagnostic stocks are recovering? EKF's core business is recovering and testing volumes are expanding! | wan | |
10/11/2020 08:56 | Not really mate - it is the investor community who had already reacted way prior to the release. I made the point a few days ago that price action proceeds fundamentals. That is what is in play. For the avoidance of doubt - I am not having a go at anyone. Just a (very) different point of view. That's what makes a market I hear you say. | tongosti | |
10/11/2020 08:46 | Crazy market reaction to an ahead of expectations update ! | wanttowin |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions